 |
Minimale Einzahlung $50 Exklusive Aktion |
Unser Ergebnis |
0% Kommission |
Are you looking to buy Bristol-Myers Squibb stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NYSE:BMY! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about Bristol-Myers Squibb stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company’s products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, Checkmate Pharmaceuticals, and Sensyne Health plc; clinical collaboration with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc; a discovery collaboration with Insitro, Inc.; and collaboration with Schrödinger, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Durchschnittliches Volumen
12,98 Millionen Aktien
MARKTKAPPE
$136.37 billion
Börse
NYSE
Kaufen Sie diese Aktie!
|
NAME
|
TICKER
|
INDUSTRIE
|
SECTOR
|
VOLUME
|
KAUFEN SIE DIESE AKTIE JETZT
|
|---|---|---|---|---|---|
|
NYSE:BMY
|
Pharmazeutische Präparate
|
Medizinisch
|
437,820 shs
|
Below is a quick guide on how to buy NYSE:BMY stocks safe, fast and around the world in less than five minutes.
Schritt 1: Eröffnen Sie ein Konto bei eToro – eToro is the best broker to buy Bristol-Myers Squibb shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Schritt 2: Laden Sie Ihre ID hoch - Gemäß den KYC-Vorschriften wird eToro Sie bitten, eine Kopie Ihres Reisepasses oder Führerscheins hochzuladen.
Schritt 3: Geld einzahlen - Zahlen Sie etwas Geld auf Ihr neu eingerichtetes eToro Konto ein. Sie können zwischen Banküberweisung, E-Wallet, Debit-/Kreditkarte oder Paypal wählen.
Schritt 4: Buy Bristol-Myers Squibb – Search for “”NYSE:BMY”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought Bristol-Myers Squibb stocks with 0% commission!.
1 | | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
15 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Bristol-Myers Squibb in the last year. There are currently 4 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should “buy” Bristol-Myers Squibb stock.
Wall Street analysts have given Bristol-Myers Squibb a “Buy” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Bristol-Myers Squibb wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
2 |  | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
3 |  | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NYSE:BMY stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy Bristol-Myers Squibb stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy Bristol-Myers Squibb stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Da es sich bei eToro um eine regulierte Plattform handelt, müssen Sie das KYC-Verfahren abschließen. Dies ist gängige Praxis und dauert nur ein paar Minuten. Sie müssen einen Lichtbildausweis (Reisepass, Führerschein) und einen Adressnachweis (Stromrechnung, Kontoauszug) vorlegen.
Sobald Sie sich angemeldet und Ihr Konto verifiziert haben, müssen Sie Geld einzahlen. eToro akzeptiert Kredit-/Debitkarten, Banküberweisungen und auch E-Wallets. Was auch immer Sie bevorzugen, es wird etwas für Sie dabei sein.
Now that you’ve funded your eToro account, just type “NYSE:BMY stocks" in die Suchleiste am oberen Rand des Bildschirms ein und drücken Sie auf "Handeln".
All that’s left is to buy some NYSE:BMY stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NYSE:BMY is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy Bristol-Myers Squibb stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) issued its quarterly earnings results on Wednesday, February, 3rd. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.04. The biopharmaceutical company earned $11.07 billion during the quarter, compared to analysts’ expectations of $10.74 billion. Bristol-Myers Squibb had a negative net margin of 0.11% and a positive trailing twelve-month return on equity of 27.48%. The firm’s revenue was up 39.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.22 EPS.
View Bristol-Myers Squibb’s earnings history.
Bristol-Myers Squibb’s stock was trading at $108.24 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BMY shares have decreased by 43.4% and is now trading at $61.30.
Bristol-Myers Squibb announced a quarterly dividend on Thursday, December 10th. Investors of record on Monday, January 4th will be paid a dividend of $0.49 per share on Monday, February 1st. This represents a $1.96 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Thursday, December 31st. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.45.
View Bristol-Myers Squibb’s dividend history.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NYSE:BMY stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Mehr als 95% der Kundengelder werden offline, in kalten Lagern, aufbewahrt, was für jeden Broker, der Ihr Vermögen verwaltet, entscheidend ist. Unabhängig davon, wie sicher eine Plattform sein soll, empfehlen wir die Verwendung von 2FA, um eine zusätzliche Sicherheitsebene für Ihr Konto zu schaffen.
eToro bietet Nutzern eine Reihe von Funktionen, um so schnell wie möglich mit dem Investieren zu beginnen. Es gibt eine relativ einzigartige Funktion namens Copy Trading, mit der Sie ein passives Einkommen erzielen können, indem Sie erfahrene Händler spiegeln. So können Sie schnell Gewinne erzielen und erhalten ein besseres Verständnis für die Strategien, die von Profis verwendet werden. Außerdem können Sie bei eToro in verwaltete Portfolios investieren. Ein verwaltetes Portfolio besteht aus einer Vielzahl ähnlicher Vermögenswerte, die in Gruppen zusammengefasst sind. Wenn Sie bereits über Handelserfahrung verfügen, können Sie auch in andere Märkte als Aktien investieren, da eToro den Handel mit ETFs, Rohstoffen, Kryptowährungen und Indizes ermöglicht. Wenn Sie bereits außerhalb des Aktienmarktes investieren, kann dies sehr nützlich sein, da Sie so alle Ihre Investitionen an einem einzigen Ort verwalten können.
Bristol-Myers Squibb pays an annual dividend of $1.96 per share and currently has a dividend yield of 3.22%. Bristol-Myers Squibb does not yet have a strock track record of dividend growth. The dividend payout ratio of Bristol-Myers Squibb is 41.79%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bristol-Myers Squibb will have a dividend payout ratio of 26.78% next year. This indicates that Bristol-Myers Squibb will be able to sustain or increase its dividend.
View Bristol-Myers Squibb’s dividend history.
Bristol-Myers Squibb shares split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were distributed to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Bristol-Myers Squibb stock prior to the split would have 200 shares after the split.
CFDs sind komplexe Instrumente und bergen aufgrund der Hebelwirkung ein hohes Risiko, schnell Geld zu verlieren. 68% der Konten von Kleinanlegern verlieren Geld beim Handel mit CFDs bei diesem Anbieter. Sie sollten sich überlegen, ob Sie verstehen, wie CFDs funktionieren und ob Sie das hohe Risiko, Ihr Geld zu verlieren, eingehen können.
Bristol-Myers Squibb issued an update on its FY 2021 Pre-Market earnings guidance on Thursday, February, 4th. The company provided EPS guidance of 7.35-7.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.45.
15 brokerages have issued 1-year price targets for Bristol-Myers Squibb’s stock. Their forecasts range from $65.00 to $88.00. On average, they anticipate Bristol-Myers Squibb’s share price to reach $74.27 in the next twelve months. This suggests a possible upside of 21.2% from the stock’s current price.
View analysts’ price targets for Bristol-Myers Squibb or view top-rated stocks among Wall Street analysts.
Bristol-Myers Squibb saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 19,730,000 shares, an increase of 31.4% from the December 31st total of 15,020,000 shares. Based on an average daily trading volume, of 10,760,000 shares, the days-to-cover ratio is currently 1.8 days.
View Bristol-Myers Squibb’s Short Interest.
Bristol-Myers Squibb’s management team includes the following people:
Dr. Giovanni Caforio, Chairman & CEO (Age 56, Pay $6.22M)
Mr. David V. Elkins, Exec. VP & CFO (Age 53, Pay $3.62M)
Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 60, Pay $2.92M)
Dr. Christopher S. Boerner, Exec. VP & Chief Commercialization Officer (Age 50, Pay $2.49M)
Mr. Rupert Vessey M.A., Exec. VP and Pres of Research & Early Devel. (Age 56, Pay $3.31M)
Mr. Paul von Autenried, Exec. VP & Chief Information Officer (Age 59)
Mr. Timothy Power, VP & Head of Investor Relations
Mr. Adam Dubow, Sr. VP, Chief Compliance & Ethics Officer (Age 54)
Ms. Ann M. Powell Judge, Exec. VP & Chief HR Officer (Age 55)
Mr. Louis S. Schmukler, Exec. VP and Pres of Global Product Devel. & Supply (Age 65)
1 | | Minimale Einzahlung $50 Exklusive Aktion | Unser Ergebnis 10 ★★★★★ | 0% Kommission |
659 employees have rated Bristol-Myers Squibb CEO Giovanni Caforio on Glassdoor.com. Giovanni Caforio has an approval rating of 89% among Bristol-Myers Squibb’s employees.
Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Endo International (ENDP) and Supernus Pharmaceuticals (SUPN).
View all of BMY’s competitors.
Based on aggregate information from Reportlab watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).
Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol “BMY.”
Bristol-Myers Squibb’s stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Swiss National Bank (0.38%), Sumitomo Mitsui Trust Holdings Inc. (0.38%), New York State Teachers Retirement System (0.14%), AMF Pensionsforsakring AB (0.11%), State of Michigan Retirement System (0.10%) and State of Wisconsin Investment Board (0.10%). Company insiders that own Bristol-Myers Squibb stock include Adam Dubow, Autenried Paul Von, Dinesh C Paliwal, Ernest Mario, Giovanni Caforio, John E Elicker, Joseph Eid, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini, Rupert Vessey, Sandra Leung, Terrie Curran and Theodore R Samuels II.
View institutional ownership trends for Bristol-Myers Squibb.
BMY stock was sold by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board, Sumitomo Mitsui Trust Holdings Inc., Gabelli Funds LLC, PGGM Investments, Swiss National Bank, Clear Harbor Asset Management LLC, Robeco Institutional Asset Management B.V., and Gabalex Capital Management LLC. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Adam Dubow, Autenried Paul Von, Giovanni Caforio, John E Elicker, Joseph Eid, Louis S Schmukler, Rupert Vessey, and Sandra Leung.
View insider buying and selling activity for Bristol-Myers Squibb or view top insider-selling stocks.
Wir von Reportlab.org möchten sicherstellen, dass Sie alle wichtigen Informationen über Aktien kaufen. Wir bieten Ihnen die besten Leitfäden zum Thema Börse mit persönlichen Bewertungen, Hintergrundinformationen, Plattformbewertungen, Anleitungen und mehr. Möchten Sie weitere Informationen erhalten? Dann schauen Sie sich die OTC-Aktien, NASDAQ-Aktien, NYSE-Aktien, LON-Aktien, FRA-Aktien, ETR-Aktien, EPA-Bestände, TSX-Aktien oder Amex Aktien. Sie suchen nach detaillierteren Informationen wie 5g Vorräte, Biotech-Aktien, Goldvorräte und andere Informationen aus unserem Reportlab.
How to buy Bristol-Myers Squibb stocks?
The safest and easiest way to buy NYSE:BMY stocks is by using a regulated broker like eToro or DEGiro. You can open an account with the platform, make a deposit and buy this stock in under 5 minutes from start to finish.
Die Eröffnung eines Kontos bei einem dieser Broker ist ein kluger Schachzug, denn sie sind seit mehr als 10 Jahren aktiv, sehr sicher in der Nutzung und bieten die beste Plattform für Anfänger und erfahrene Händler. Wenn Sie mehr erfahren möchten, dann empfehlen wir Ihnen, unseren eToro oder DeGiro Ratgeber.
Where to buy Bristol-Myers Squibb stock?
You will first want to find a licensed broker that supports Bristol-Myers Squibb stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NYSE:BMY stocks in a safe and complete environment.
Is NYSE:BMY stock a good investment?
As with any other asset, there is an element of risk associated with buying NYSE:BMY stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is Bristol-Myers Squibb stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NYSE:BMY is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in Bristol-Myers Squibb stock.
How do you trade Bristol-Myers Squibb stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for Bristol-Myers Squibb stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NYSE:BMY stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell Bristol-Myers Squibb stock?
To sell your NYSE:BMY stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best Bristol-Myers Squibb stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NYSE:BMY stock.
Stephen kennt sich gut mit Finanzprodukten aus und hat insbesondere eine große Leidenschaft für die Aktienmärkte und ihre Teilnehmer. Wir hoffen, dass die bereitgestellten Informationen Ihnen helfen werden. Ist Ihnen etwas nicht ganz klar? Bitte hinterlassen Sie Ihre Fragen oder Kommentare unten auf der Seite.
| Unser Ergebnis ★★★★★ | |
| Unser Ergebnis ★★★★★ | |
| Unser Ergebnis ★★★★★ |
Newsletter
Neueste Nachrichten
| |
Unser Ergebnis |
0% Kommission |
Top 10 5G Aktien Mehr Informationen 5G Aktien Top 10 Beste 5G Aktien zum Kaufen
Aktien & Krypto-Daten in Echtzeit
Benachrichtigungen, Tipps & Neuigkeiten
Beste Aktien & Krypto-Führer
Online Broker & Börse Bewertungen
Reportlab Finanzen ist eine rein informative Website und stellt in keinem Fall eine Anlageberatung dar. Alle Investitionen sind mit Risiken verbunden und Sie können Ihre gesamten Investitionen verlieren. Investieren Sie kein Geld, das Sie sich nicht leisten können, zu verlieren.
Reportlab Finanzen
38 Holburn Lane
Heckfield Green
IP21 0UB
Vereinigtes Königreich
Copyright © 2022 Reportlab.Finance | Alle Rechte vorbehalten.
